What this study is
A newly published study in Annals of Rheumatic Diseases used biosamples supported by Cure JM Centers of Excellence and the CARRA Registry to analyze nearly 3,000 blood proteins in children newly diagnosed with juvenile dermatomyositis (JDM). Researchers examined samples collected at diagnosis and again six months after treatment began to better understand how disease activity changes over time.
This large, multicenter North American study reflects years of collaboration among families, clinicians, researchers, Cure JM, and CARRA.
What researchers found
The study identified specific protein “signatures” linked to:
- Ongoing immune activation that can persist even after treatment starts
- Blood vessel (endothelial) dysfunction, reinforcing the central role of vasculopathy in JDM
- Distinct biological patterns associated with myositis-specific autoantibodies, including NXP2 and MDA5
Notably, some inflammatory and vascular signals remained active even when traditional lab markers improved, highlighting gaps in how disease activity is currently monitored.
Why this matters
Today’s commonly used blood tests do not always reflect ongoing inflammation or tissue damage in JDM, especially as disease activity becomes lower or more complex. This study helps address that gap by identifying proteins that may better track disease activity across muscle, skin, and blood vessels.
The findings also support a more personalized approach to care, where children with different autoantibody subtypes may benefit from more tailored monitoring and treatment strategies.
Cure JM’s role
This research would not have been possible without Cure JM’s long-term investment in Centers of Excellence, biospecimen collection, and collaborative infrastructure. By supporting high-quality sample collection and patient-centered research partnerships, Cure JM continues to accelerate discoveries that move the field toward better biomarkers, targeted therapies, and precision medicine for children with JDM.
What’s next
These findings lay the groundwork for future studies to validate new biomarker panels and explore treatment strategies that address persistent inflammation and vascular involvement in JDM.
Read the full study: https://doi.org/10.1016/j.ard.2025.07.020
